Advertisement
Canada markets close in 54 minutes
  • S&P/TSX

    21,760.55
    +52.11 (+0.24%)
     
  • S&P 500

    4,957.52
    -53.60 (-1.07%)
     
  • DOW

    37,895.29
    +119.91 (+0.32%)
     
  • CAD/USD

    0.7272
    +0.0008 (+0.11%)
     
  • CRUDE OIL

    83.23
    +0.50 (+0.60%)
     
  • Bitcoin CAD

    88,305.03
    +1,242.66 (+1.43%)
     
  • CMC Crypto 200

    1,334.09
    +21.47 (+1.58%)
     
  • GOLD FUTURES

    2,412.30
    +14.30 (+0.60%)
     
  • RUSSELL 2000

    1,933.23
    -9.73 (-0.50%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,239.99
    -361.51 (-2.32%)
     
  • VOLATILITY

    19.17
    +1.17 (+6.50%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

A Look At The Intrinsic Value Of HCA Healthcare, Inc. (NYSE:HCA)

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

How far off is HCA Healthcare, Inc. (NYSE:HCA) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. I will use the Discounted Cash Flows (DCF) model. Don’t get put off by the jargon, the math behind it is actually quite straightforward. If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model. If you are reading this and its not February 2019 then I highly recommend you check out the latest calculation for HCA Healthcare by following the link below.

See our latest analysis for HCA Healthcare

Is HCA fairly valued?

I’m using the 2-stage growth model, which simply means we take in account two stages of company’s growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have perpetual stable growth rate. In the first stage we need to estimate the cash flows to the business over the next five years. For this I used the consensus of the analysts covering the stock, as you can see below. I then discount this to its value today and sum up the total to get the present value of these cash flows.

5-year cash flow forecast

2019

2020

2021

2022

2023

Levered FCF ($, Millions)

$3.12k

$3.25k

$2.97k

$4.12k

$4.36k

Source

Analyst x6

Analyst x8

Analyst x3

Analyst x1

Est @ 5.88%

Present Value Discounted @ 11.32%

$2.81k

$2.63k

$2.16k

$2.68k

$2.55k

Present Value of 5-year Cash Flow (PVCF)= US$13b

ADVERTISEMENT

The second stage is also known as Terminal Value, this is the business’s cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at an annual growth rate equal to the 10-year government bond rate of 2.7%. We discount this to today’s value at a cost of equity of 11.3%.

Terminal Value (TV) = FCF2023 × (1 + g) ÷ (r – g) = US$4.4b × (1 + 2.7%) ÷ (11.3% – 2.7%) = US$52b

Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = US$52b ÷ ( 1 + 11.3%)5 = US$31b

The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is US$43b. The last step is to then divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) then we use the equivalent number. This results in an intrinsic value of $125.96. Relative to the current share price of $139.53, the stock is fair value, maybe slightly overvalued at the time of writing.

NYSE:HCA Intrinsic Value Export February 11th 19
NYSE:HCA Intrinsic Value Export February 11th 19

The assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don’t have to agree with my inputs, I recommend redoing the calculations yourself and playing with them. Because we are looking at HCA Healthcare as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 11.3%, which is based on a levered beta of 1.182. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, DCF calculation shouldn’t be the only metric you look at when researching a company. For HCA, I’ve put together three essential aspects you should further research:

  1. Financial Health: Does HCA have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.

  2. Future Earnings: How does HCA’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of HCA? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St does a DCF calculation for every US stock every 6 hours, so if you want to find the intrinsic value of any other stock just search here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.